BridgeBio Pharma
BBIO
BBIO
303 hedge funds and large institutions have $6.41B invested in BridgeBio Pharma in 2025 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 120 increasing their positions, 79 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
15% more funds holding
Funds holding: 263 → 303 (+40)
3.88% more ownership
Funds ownership: 93.48% → 97.36% (+3.9%)
Holders
303
Holding in Top 10
18
Calls
$472M
Puts
$80.1M
Top Buyers
| 1 | +$76.3M | |
| 2 | +$66.8M | |
| 3 | +$56.5M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$51.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$50.6M |
Top Sellers
| 1 | -$202M | |
| 2 | -$103M | |
| 3 | -$28.1M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$25.8M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$25.7M |